Janssen, a Johnson & Johnson company, has announced that its bispecific antibody has been granted approval by the European Commission (EC) for use in certain patients with relapsed or refractory multiple myeloma (RRMM).
Actimed Therapeutics Ltd will put some of its additional funding of £4.75 million ($6 million) towards its attempt to provide the world’s first cure for cancer cachexia.
Talus Bioscience, a drug discovery company developing new treatments for cancer, inflammation, and other diseases, has announced $4.3 million in non-dilutive grant funding across three new awards.
Throughout 2023, the life sciences industry has been faced with many operational issues, including supply-chain uncertainty, inflation, and talent shortages.
Absci, a leader in AI drug creation, and the California Institute of Technology (Caltech) have received a grant from the Bill & Melinda Gates Foundation.
MEI Pharma has dosed the first patient in its phase 1 study evaluating ME-344 in combination with bevacizumab (AVASTIN) in patients with previously treated metastatic colorectal cancer.
BioPharma Reporter and Outsourcing Pharma presents its latest round-up of the movers and shakers in the pharma industry. From Karuna Therapeutics to IO Biotech, we break down the key changes on the pharmaceutical job ladder.
Genprex has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead candidate, Reqorsa immunogene therapy (quaratusugene ozeplasmid), for the treatment of small cell lung cancer (SCLC).
Vaxxinity has announced the publication of its phase 2 clinical trial data for UB-311, stating that the treatment was safe, well-tolerated and demonstrated a trend for slowing cognitive decline in mild Alzheimer's disease (AD).
Digital biomarker company Koneksa has launched the first collaboration in the Koneska Academic Partnership Program for Parkinson’s Disease (KAPP-PD) to incorporate its Neuroscience Toolkit into research programs.
A new treatment for erectile dysfunction (ED) has received regulatory approval in the Kingdom of Saudi Arabia, a key ED market, with 10.45% of married males experiencing the condition.
Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.
Lonza has launched the Nebula Absorbance Reader, a new absorbance microplate reader, which joins the company’s portfolio of optimized instruments for streamlined endotoxin and pyrogen testing.
AGC Biologics, a global contract development and manufacturing organization (CDMO), has completed the expansion of its manufacturing space at its Milan Cell and Gene Center of Excellence production site.
Evox Therapeutics, an exosome therapeutics company, has announced the publication of its research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes.
Sigma Mostafa is the chief scientific officer of KBI Biopharma, a development and contract manufacturing organization serving the biopharmaceutical industry.
Terumo Blood and Cell Technologies have announced US Food and Drug Administration (FDA) clearance of the Reveos Automated Whole Blood Processing System.
A new report from Angelini Pharma has highlighted an ongoing treatment gap for epilepsy care in Europe, including significant differences in access to treatment between countries.
BlueRock Therapeutics, a clinical stage cell therapy company, and bit.bio, the company coding human cells for novel cures, have announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs)...
Evox Therapeutics, an exosome therapeutics company, has announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai in New York, US.
NK:IO, a leader in natural killer (NK) cell biology applied to the development of potent, off-the-shelf cell therapies targeting solid tumors, has raised £1.2m.
Renaissance Pharma, a company focused on the development of life changing therapies in pediatric rare disease, has entered into an exclusive license agreement with St. Jude Children’s Research Hospital for Hu14.18, a humanised antibody in development...
Epsilogen, a leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, has published phase 1 data from the first ever clinical trial of an IgE antibody therapeutic in Nature Communications.
Bora Pharmaceuticals, an international contract development and manufacturing organization (CDMO), has announced the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.
IO Biotech, a clinical-stage biopharma company developing novel, immune-modulating cancer vaccines based on its T-win technology platform, has dosed the first patient in its phase 1 bladder cancer trial.
Boston-based pharma company Ratio Therapeutics has initiated dosing in a phase 1 study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, RTX-1363S,...
Biovian, a leading contract development and manufacturing organization (CDMO) specializing in biopharmaceuticals, has announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland.
Leslie Orne joined Trinity Life Sciences in 2001 and was recently appointed CEO and president of the fast-growing healthcare consultancy. She previously held the title of chief commercial officer (CCO) and president.
Gilead Sciences has decided to end a phase 3 trial of magrolimab for higher-risk myelodysplastic syndromes (MDS) after an analysis suggested it would be futile to continue.
ImmunoGen, a biotech company focused on the development of antibody-drug conjugate (ADC) technology to treat cancer, has announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem, a biopharma firm...
Teva Pharmaceuticals, a provider of generic and innovative medicines, and Alvotech, a biotech company specializing in the development and manufacture of biosimilar medicines, have expanded their existing partnership agreement.
LinKinVax, a clinical-stage biotech company, has announced the manufacture and bottling of a GMP batch of its next generation pan-sarbecovirus vaccines, known as PanCov, designed to prevent COVID-19 and other known coronavirus diseases.
Janssen Pharmaceuticals has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Talvey (talquetamab).
MaaT Pharma, a clinical-stage biotech company focused on the development of Microbiome Ecosystem Therapies (MET) dedicated to improving survival outcomes for patients with cancer, is now a member of Microbiome Therapeutics Innovation Group (MTIG).
PrecisionLife, a computational biology company driving precision medicine in complex chronic diseases, has announced the results of its long COVID study, providing the first detailed genetic insights into the condition and its commonalities with other...
London-based precision medicine software provider Lifebit has partnered with two population genomic initiatives in Mexico and Brazil to help diversify genomic research and reduce health inequality in Latin America.
Twist Bioscience, a biotech company manufacturing synthetic DNA, and Cancer Research Horizons, the innovation engine at the core of Cancer Research UK, have announced an agreement under which Cancer Research Horizons will license the entire Twist Biopharma...
Liz Beatty is co-founder and chief strategy officer at Inato, a clinical trials platform which flips the traditional model and allows community sites to participate in the trials that are best aligned with their interests and that of their patients.
Johnson and Johnson (J&J) recently granted permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries.